Advertisement
Screener

CRISPR THERAPEUTICS AG (CRSP) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

CRISPR THERAPEUTICS AG Increase (Decrease) in Deferred Revenue

CRISPR THERAPEUTICS AG (CRSP) reported Increase (Decrease) in Deferred Revenue of -$244.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-07.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-08-07

  • CRISPR THERAPEUTICS AG increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$26.00K, a 102.82% decline year-over-year.
  • CRISPR THERAPEUTICS AG increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$218.00K, a 132.78% decline year-over-year.
  • CRISPR THERAPEUTICS AG increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$22.76M, a 3365.57% decline year-over-year.
  • CRISPR THERAPEUTICS AG increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $457.00K, a 10.39% decline year-over-year.
  • CRISPR THERAPEUTICS AG increase (decrease) in deferred revenue for fiscal 2017 was -$20.72M, a 1180.75% decline from fiscal 2016.
  • CRISPR THERAPEUTICS AG increase (decrease) in deferred revenue for fiscal 2016 was $1.92M, a 97.45% decline from fiscal 2015.
  • CRISPR THERAPEUTICS AG increase (decrease) in deferred revenue for fiscal 2015 was $75.09M.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2018-06-30-$26.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
-$244.00K
10-Q · filed 2018-08-07
-$23.00M
derived: sum of 3 quarters · filed 2018-08-07
-$22.55M
derived: sum of 4 quarters · filed 2018-08-07
2018-03-31-$218.00K
10-Q · filed 2018-05-08
-$22.98M
derived: sum of 2 quarters · filed 2018-05-08
-$22.52M
derived: sum of 3 quarters · filed 2018-05-08
-$21.60M
derived: sum of 4 quarters · filed 2018-08-07
2017-12-31-$22.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
-$22.30M
derived: sum of 2 quarters · filed 2018-03-08
-$21.38M
derived: sum of 3 quarters · filed 2018-08-07
-$20.72M
10-K · filed 2018-03-08
2017-09-30$457.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$1.38M
derived: sum of 2 quarters · filed 2018-08-07
$2.04M
10-Q · filed 2017-11-08
$2.74M
derived: sum of 4 quarters · filed 2018-08-07
2017-06-30$921.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
$1.59M
10-Q · filed 2018-08-07
$2.28M
derived: sum of 3 quarters · filed 2018-08-07
$2.79M
derived: sum of 4 quarters · filed 2018-08-07
2017-03-31$665.00K
10-Q · filed 2018-05-08
$1.36M
derived: sum of 2 quarters · filed 2018-05-08
$1.87M
derived: sum of 3 quarters · filed 2018-05-08
$2.43M
derived: sum of 4 quarters · filed 2018-05-08
2016-12-31$697.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
$1.21M
derived: sum of 2 quarters · filed 2018-03-08
$1.77M
derived: sum of 3 quarters · filed 2018-03-08
$1.92M
10-K · filed 2018-03-08
2016-09-30$510.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$1.07M
derived: sum of 2 quarters · filed 2017-11-08
$1.22M
10-Q · filed 2017-11-08
2016-06-30$559.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10
$710.00K
10-Q · filed 2017-08-10
2016-03-31$151.00K
10-Q · filed 2017-05-11
2015-12-31$75.09M
10-K · filed 2018-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B